U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Advisory Committees
  3. Committees and Meeting Materials
  4. Human Drug Advisory Committees
  5. Bone, Reproductive and Urologic Drugs Advisory Committee (formerly Reproductive Health Drugs Advisory Committee)
  6. Waiver for Conflicts of Interest for the October 30, 2019 Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC)
  1. Bone, Reproductive and Urologic Drugs Advisory Committee (formerly Reproductive Health Drugs Advisory Committee)

Waiver for Conflicts of Interest for the October 30, 2019 Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC)

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance

Disclaimer

The Food and Drug Administration Amendments Act of 2007 (FDAAA), enacted on September 27, 2007, added a new provision regarding financial conflicts of interest, § 712 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), effective October 1, 2007. Accordingly, for advisory committee meetings after October 1, 2007, FDA is granting waivers under 18 U.S.C. § 208 and § 712 of the FD&C Act, where applicable, when the relevant waiver standards in these statutes are met.

Waivers under 21 U.S.C. § 355(n)(4) were issued before October 1, 2007.  This provision was repealed, effective October 1, 2007, by the FDA.

David Eisenberg, M.D., MPH

Back to Top